REG - Feedback PLC - Trading Update & Director Appointment

FeedbackAnnouncement

01/06/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220601:nRSA4500Na&default-theme=true

RNS Number : 4500N  Feedback PLC  01 June 2022
Feedback plc

 

Trading Update and Director Appointment

 

·    Trading for the financial year ended 31 May 2022 materially ahead of
market expectations

·    Annemijn Eschauzier joins the Board adding strong healthcare and
digital skill sets, as Tim Irish steps down

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical
communication company, is pleased to announce that it has continued its strong
momentum into the second half of 2022 and now expects to report revenue for
the financial year ended 31 May 2022 materially ahead of market expectations.
This follows the previously announced progress with the Company's flagship
product Bleepa(®) and additional technology license fees arising from the
Company's partnership with Imaging Engineering LLC (partnership as announced
13 January 2020) booked at the year-end. The Board expects to provide a full
2022 year-end operational and trading update in mid-June 2022.

 

Appointment of Annemijn Eschauzier to the Board

Annemijn Eschauzier has been appointed to the Board of directors as a
Non-Executive Director with immediate effect.

 

Annemijn brings significant global leadership experience with a career
spanning well over 25 years in the Healthcare sector. She started her career
at GlaxoSmithKline before moving to GE Healthcare, where she held a variety of
leadership positions for over 15 years becoming Chief Marketing Officer
Women's Health in September 2017. Since leaving GE Healthcare in March 2021,
Annemijn has joined Hardian Health, a company which provides strategic
services to navigate the digital health sector. In addition, Annemijn. holds
other non-statutory Board member roles and has a bachelor's degree in Dutch
Law and Business Administration.

 

Annemijn will be joining the Board as Tim Irish steps down as NED with
immediate effect, after five years with the Company. Tim leaves to pursue new
opportunities in the medical sector.

 

Rory Shaw, Chairman of Feedback, commented: "We are delighted to report that
revenue is expected to be materially ahead of expectations. Importantly, we
are developing relationships with existing and new partners and believe that
we are at an inflection point for growth as we continue to see the benefits of
investing the funds raised last year.

 

"We are delighted to welcome Annemijn to the Board and believe that she will
bring a wealth of experience as we steer the Company ever faster towards the
commercial growth of our technologies. The Board and I would like to sincerely
thank Tim Irish for his fantastic service to the Company over the course of
his five years as a NED, we wish him well in all his future endeavours and are
delighted that he remains such a strong advocate for the company and our
technologies as he goes forward in his new roles"

 

Anna Marina ("Annemijn") Eschauzier (aged 64) does not currently hold any
directorships and has no previous directorships (within 5 years). Annemijn
Eschauzier has confirmed that there is no further information to be disclosed
pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

 

Further information on Feedback and its products can be found on the Company's
website: https://fbkmed.com/feedback-plc/reports-and-presentations/
(https://fbkmed.com/feedback-plc/reports-and-presentations/)

 

Enquiries:

 

 Feedback plc                                    +44 (0) 20 3997 7634

 Tom Oakley, CEO                                 IR@fbk.com (mailto:IR@fbk.com)

 Anesh Patel, CFO

 Panmure Gordon (UK) Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Freddy Crossley (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd                                 Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                                 (mailto:feedbackplc@walbrookpr.com)
 Paul McManus/Nick Rome                          07980 541 893 or 07748 325 236

 

About Feedback

 

Feedback plc is a specialist clinical communications business, with a mission
to improve the efficiency and quality of communications for frontline
clinicians and hospitals with a key focus on building solutions that enhance
access to high quality patient data.

 

Feedback has developed a toolkit of clinical communications apps. Its core,
regulatory approved product is Bleepa, a revolutionary medical imaging app
enabling remote and secure communications between frontline clinicians and
teams. CareLocker is an evolutionary GDPR compliant patient-centric cloud
architecture - its proprietary technology enables an easy route to creation
and mobilisation of individual healthcare records. Bleepa Box is a specialist
tool to enable image transfer from remote settings to the Bleepa platform over
mobile networks.

 

The Company has a number of growth opportunities domestically and
internationally across a range of markets including the NHS, the veterinary
market and private healthcare providers and its highly scalable Software as a
Service ("SaaS")-based revenue model is expected to provide increasing levels
of visibility as the Company grows its customer base.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTEALSFDSNAEFA